WallStreetZenWallStreetZen

NASDAQ: LIFE
Atyr Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for LIFE

Based on 4 analysts offering 12 month price targets for Atyr Pharma Inc.
Min Forecast
$9.00+296.48%
Avg Forecast
$19.00+737%
Max Forecast
$35.00+1,441.85%

Should I buy or sell LIFE stock?

Based on 4 analysts offering ratings for Atyr Pharma Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LIFE stock forecasts and price targets.

LIFE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 10%
91
BuyReiterates$35.00+1,441.85%2023-05-23
RBC Capital
Top 4%
97
BuyReiterates$19.00+737.00%2023-05-10
Piper Sandler
Top 23%
78
Strong BuyMaintains$13.00+472.69%2023-04-11
Roth MKM
Bottom 2%
2
Strong BuyReinstates$9.00+296.48%2023-03-06

1 of 1

Forecast return on equity

Is LIFE forecast to generate an efficient return?
Company
N/A
Industry
0.07%
Market
71.27%

Forecast return on assets

Is LIFE forecast to generate an efficient return on assets?
Company
N/A
Industry
0.1%

LIFE revenue growth forecast

How is LIFE forecast to perform vs Biotechnology companies and vs the US market?
Company
58.6%
Industry
39.99%
Market
8.44%
LIFE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LIFE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LIFE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LIFE$2.27$19.00+737.00%Strong Buy
GLYC$1.92$8.00+316.67%Buy
CMRX$1.39$9.00+547.48%Buy
MIST$3.70$19.00+413.51%Buy
STTK$2.87$21.00+631.71%Buy
View Top Biotech Stocks

Atyr Pharma Stock Forecast FAQ

Is Atyr Pharma Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: LIFE) stock is to Strong Buy LIFE stock.

Out of 4 analysts, 2 (50%) are recommending LIFE as a Strong Buy, 2 (50%) are recommending LIFE as a Buy, 0 (0%) are recommending LIFE as a Hold, 0 (0%) are recommending LIFE as a Sell, and 0 (0%) are recommending LIFE as a Strong Sell.

If you're new to stock investing, here's how to buy Atyr Pharma stock.

What is LIFE's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: LIFE) forecast ROE is N/A, which is considered weak.

What is LIFE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year LIFE price target, the average LIFE price target is $19.00, with the highest LIFE stock price forecast at $35.00 and the lowest LIFE stock price forecast at $9.00.

On average, Wall Street analysts predict that Atyr Pharma's share price could reach $19.00 by May 23, 2024. The average Atyr Pharma stock price prediction forecasts a potential upside of 737% from the current LIFE share price of $2.27.

What is LIFE's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: LIFE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.1%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.